S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
NASDAQ:APTO

Aptose Biosciences (APTO) Stock Price, News & Analysis

$1.62
+0.12 (+8.00%)
(As of 12:32 PM ET)
Today's Range
$1.50
$1.64
50-Day Range
$1.40
$2.20
52-Week Range
$1.36
$9.90
Volume
40,779 shs
Average Volume
90,348 shs
Market Capitalization
$25.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.80

Aptose Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,220.0% Upside
$19.80 Price Target
Short Interest
Healthy
0.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Aptose Biosciences in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

438th out of 939 stocks

Biological Products, Except Diagnostic Industry

65th out of 156 stocks

APTO stock logo

About Aptose Biosciences Stock (NASDAQ:APTO)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Stock Price History

APTO Stock News Headlines

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Recap: Aptose Biosciences Q4 Earnings
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Why Is Aptose Biosciences (APTO) Stock Down Today?
Aptose Biosciences Inc APTO
Aptose Biosciences: Q3 Earnings Insights
Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)
See More Headlines
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/23/2023
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.80
High Stock Price Target
$38.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,220.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-41,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.13 per share

Miscellaneous

Free Float
14,220,000
Market Cap
$23.58 million
Optionable
No Data
Beta
1.30
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

APTO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price target for 2024?

5 Wall Street research analysts have issued 1 year target prices for Aptose Biosciences' shares. Their APTO share price targets range from $5.00 to $38.00. On average, they expect the company's stock price to reach $19.80 in the next twelve months. This suggests a possible upside of 1,220.0% from the stock's current price.
View analysts price targets for APTO
or view top-rated stocks among Wall Street analysts.

How have APTO shares performed in 2024?

Aptose Biosciences' stock was trading at $2.54 at the start of the year. Since then, APTO shares have decreased by 40.9% and is now trading at $1.50.
View the best growth stocks for 2024 here
.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 50,200 shares, a decrease of 28.7% from the February 29th total of 70,400 shares. Based on an average daily volume of 93,300 shares, the short-interest ratio is currently 0.5 days. Currently, 0.5% of the shares of the stock are sold short.
View Aptose Biosciences' Short Interest
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our APTO earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its earnings results on Thursday, March, 23rd. The biotechnology company reported ($1.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.65). During the same period in the previous year, the firm posted ($4.05) earnings per share.

When did Aptose Biosciences' stock split?

Aptose Biosciences shares reverse split on the morning of Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (0.80%), Sigma Planning Corp (0.95%), Citadel Advisors LLC (0.41%), Texas Capital Bank Wealth Management Services Inc (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends
.

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APTO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners